Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680508 · ClinicalTrials.gov registry record · Phase 2
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
A Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by University of Hawaii.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT03680508: Active Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by University of Hawaii.
NCT03680508 is a Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer that is active but no longer recruiting, run by University of Hawaii. The registered enrollment target is 42 participants, above the 24-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (75% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680508, a Phase 2 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, is active but no longer recruiting, sponsored by University of Hawaii.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) work in combination in treating patients with locally advanced or metastatic liver cancer.
Primary Outcome
Determined by RECIST v1.1 criteria
Conditions Studied
Interventions
- DRUG TSR-022 and TSR-042
Study Locations (2)
Hawaii
- University of Hawaii - Honolulu
Oregon
- Oregon Health & Science University Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What the registry record for NCT03680508 still lists
NCT03680508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, above the 24-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (75% higher).
The record links to 3 conditions, with Advanced Adult Primary Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which TSR-022 and TSR-042 is the first listed.
NCT03680508 reports a single indexed study location in Hawaii, Oregon.
Frequently Asked Questions
What is clinical trial NCT03680508 about?
NCT03680508 is a clinical study titled "TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer". TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 bind...
What is the current status of trial NCT03680508?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-12-19. Estimated completion is 2027-10.
What conditions does trial NCT03680508 study?
This clinical trial studies the following conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Adult Primary Liver Cancer.
What interventions are being tested in trial NCT03680508?
The interventions under investigation include: TSR-022 and TSR-042 (DRUG).
Who is sponsoring clinical trial NCT03680508?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680508 being conducted?
This trial has 2 study locations across Hawaii, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
COMPLETED · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI